Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
21.71
-0.50 (-2.25%)
At close: Mar 12, 2026, 4:00 PM EDT
21.56
-0.15 (-0.69%)
Pre-market: Mar 13, 2026, 5:02 AM EDT

Ultragenyx Pharmaceutical Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
673560434363.33351.41
Revenue Growth (YoY)
20.18%29.03%19.45%3.39%29.66%
Cost of Revenue
109774528.3216.01
Gross Profit
564483389335.01335.4
Selling, General & Admin
349321310278.14219.98
Research & Development
750698648705.79497.15
Total Operating Expenses
1,0991,019958983.93717.14
Operating Income
-535-536-569-648.92-381.74
Interest Income
25372711.071.93
Interest Expense
-62-63-66-43.02-29.42
Other Non-Operating Income (Expense)
1-5-1-20.87-43.75
Total Non-Operating Income (Expense)
-36-31-40-52.81-71.24
Pretax Income
-571-567-609-701.73-452.98
Provision for Income Taxes
42-25.71.04
Net Income
-575-569-607-707.42-454.03
Net Income to Common
-575-569-607-707.42-454.03
Shares Outstanding (Basic)
9991747068
Shares Outstanding (Diluted)
9991747068
Shares Change (YoY)
8.95%23.13%5.13%3.13%11.42%
EPS (Basic)
-5.83-6.29-8.25-10.12-6.70
EPS (Diluted)
-5.83-6.29-8.25-10.12-6.70
Free Cash Flow
-472-421-519-496.59-411.79
Free Cash Flow Per Share
-4.79-4.65-7.06-7.10-6.07
Gross Margin
83.80%86.25%89.63%92.21%95.44%
Operating Margin
-79.49%-95.71%-131.11%-178.60%-108.63%
Profit Margin
-85.44%-101.61%-139.86%-194.71%-129.20%
FCF Margin
-70.13%-75.18%-119.59%-136.68%-117.18%
EBITDA
-500-500-543-630.7-368.5
EBITDA Margin
-74.29%-89.29%-125.12%-173.59%-104.86%
EBIT
-535-536-569-648.92-381.74
EBIT Margin
-79.49%-95.71%-131.11%-178.60%-108.63%
Effective Tax Rate
-0.70%-0.35%0.33%-0.81%-0.23%
Updated Feb 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q